89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development
| Autor: | Nerissa Viola-Villegas, Brooke N. McKnight |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Diagnostic methods Chemistry Organic Chemistry Translational research Precision medicine Biochemistry Article 030218 nuclear medicine & medical imaging Analytical Chemistry Cancer treatment Clinical trial 03 medical and health sciences 0302 clinical medicine Drug development 030220 oncology & carcinogenesis Drug Discovery medicine Radiology Nuclear Medicine and imaging Medical physics Spectroscopy Predictive biomarker Companion diagnostic |
| Zdroj: | Journal of Labelled Compounds and Radiopharmaceuticals. 61:727-738 |
| ISSN: | 0362-4803 |
| Popis: | Therapeutic monoclonal antibodies (mAbs) have been used in cancer treatment for 30 years, with around 24 mAb and mAb:drug conjugates approved by the FDA to date. Despite their specificity, efficacy has remained limited, which, in part, derails nascent initiatives towards precision medicine. An image-guided approach to reinforce treatment decisions using immune positron emission tomography (immunoPET) companion diagnostic is warranted. This review provides a general overview of current translational research using Zr-89 immunoPET and opportunities for utilizing and harnessing this tool to its full potential. Patient case studies are cited to illustrate immunoPET probes as tools for profiling molecular signatures. Discussions on its utility in reinforcing clinical decisions as it relates to histopathological tumor assessment and standard diagnostic methods, and its potential as predictive biomarkers are presented. We finally conclude with an overview of practical considerations to its utility in the clinic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |